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Edited by Judit Ova´diAbstract The control of glucagon secretion by pancreatic a-
cells is poorly understood, largely because of the diﬃculty to rec-
ognize living a-cells. We describe a new mouse model, referred to
as GluCre-ROSA26EYFP (or GYY), allowing easy a-cell iden-
tiﬁcation because of speciﬁc expression of EYFP. GYY mice dis-
played normal glycemic control during a fasting/refeeding test or
intraperitoneal insulin injection. Glucagon secretion by isolated
islets was normally inhibited by glucose and stimulated by adren-
aline. [Ca2+]c responses to arginine, adrenaline, diazoxide and
tolbutamide, were similar in GYY and control mice. Hence, this
new mouse model is a reliable and powerful tool to speciﬁcally
study a-cells.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Insulin and glucagon, secreted by pancreatic islet b- and a-
cells, respectively, play a major but opposite role in glucose
homeostasis: insulin decreases blood glucose whereas glucagon
increases it. Alterations in b- and a-cell functions are impli-
cated in the pathogenesis of the chronic hyperglycemia of dia-
betes and in certain forms of hypoglycemia [1–4].
Whereas the mechanisms regulating insulin secretion are rel-
atively well established, those controlling glucagon secretion
are still very controversial [5]. Elucidating a-cell pathophysiol-
ogy requires measurements of various parameters at the cellu-
lar level, such as the free cytosolic Ca2+ concentration ([Ca2+]c)
which has been shown to serve as a triggering signal for exo-
cytosis of glucagon-containing granules [6,7]. However, these
experiments are diﬃcult to perform because a-cells represent
only 20% of islet cells and, in situ, are almost indistinguish-
able from the most abundant b-cells.
Several methods have been developed to purify or identify a-
cells [8–15], but none of them allows easy, reliable, and directAbbreviations: [Ca2+]c, free cytosolic calcium concentration; EYFP,
enhanced yellow ﬂuorescent protein; FACS, ﬂuorescence activated cell
sorting; KATP channel, ATP-sensitive K
+ channel
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we have developed a new transgenic mouse model, referred to
as GluCre-ROSA26EYFP or GYY mice, expressing the
enhanced yellow ﬂuorescent protein (EYFP) speciﬁcally in a-
cells. These mice were obtained by crossing two strains:
ROSA26-EYFP [16] and glucagon-Cre mice [17]. ROSA26-
EYFP mice are reporter mice that have a sequence loxP-
STOP-loxP-EYFP in the locus ROSA26 of their genome.
EYFP is not expressed unless the STOP sequence is excised
by a Cre recombinase, which recognizes loxP sites on both sides
of the STOP sequence. Glucagon-Cre mice express Cre recom-
binase speciﬁcally in a-cells because expression of the enzyme is
under control of the glucagon promoter. Hence, crossing
ROSA26-EYFP mice with glucagon-Cre mice yielded a new
strain of mice with EYFP expression restricted to a-cells. Com-
parison with two strains of control mice showed that the ﬂuo-
rescent a-cells of the GYY mouse model displayed normal
characteristics and can thus reliably be used to study a-cell
physiology.2. Materials and methods
2.1. Generation and detection of hybrid transgenic mice
Glu-Cre and RIP-Cre mice were generated as previously described
[17]. Homozygous ROSA26-EYFP (R26YY) mice were kindly given
by Dr. S. Srinivas (London, UK) [16]. Hybrid heterozygous Glu-
CreR26Y+ (GY+) mice were generated by crossing R26YY with
Glu-Cre mice. GluCreR26YY (GYY) mice were generated by crossing
GY+ mice together. The presence of Cre and ROSA26-EYFP trans-
genes was assessed by PCR genotyping as previously described
[17,18]. The same strategy was followed to obtain RIPCreR26YY (RI-
PYY) mice. NMRI and C57BL/6J mice were used as controls as indi-
cated. All experiments were performed with 4–8-month-old mice of
both genders. The study was approved by and conducted following
the guidelines of the Commission d’Ethique d’Experimentation Ani-
male of the University of Louvain School of Medicine.
2.2. In vivo analyses
Blood samples were collected from the tail vein. Blood glucose was
measured with a portable glucometer (Bayer, New York, NY). Plasma
glucagon was determined using the glucagon radioimmunoassay kit
from Linco (St. Charles, MO). For the insulin tolerance test, mice were
injected intraperitoneally with insulin (0.75 IU/kg, Actrapid, Novo-
Nordisk, Bagsvaerd, Denmark) after 6 h of fast.
2.3. Preparations, solutions and drugs
Islets were obtained by collagenase digestion of the pancreas, and
when necessary, dispersed into single cells [19]. Intact islets were cul-
tured overnight and islet cells were cultured for 1–4 days in RPMIblished by Elsevier B.V. All rights reserved.
Fig. 1. EYFP is speciﬁcally expressed in a- and b-cells from GYY and
RIPYY mice, respectively. (A–L): After immunodetection of glucagon
(C), insulin (F, L), and somatostatin (I), islet cells were visualized in
bright ﬁeld (A, D, G, J), or in ﬂuorescence with the EYFP ﬁlter set (B,
E, H, K) or with the Alexa Red 594 ﬁlter set (C, F, I, L). A–C: Two out
of three glucagon-labelled a-cells from GYY mice (C) are tagged with
EYFP (B). D–F: The EYFP-tagged cell (E) from GYY mice is not
labelled for insulin (F). G–I: The EYFP-tagged cells (H) from GYY
mice are not labelled for somatostatin (I). J–L: Both EYFP-tagged
cells (K) from RIPYY mice are labelled for insulin (L). M: Confocal
section of a GYY islet revealing distinct distribution of EYFP (green
cells) and insulin expressing cells (red cells). N: Anti-glucagon
immunohistochemistry using DAB on a pancreatic section of GYY
mice. Scale bars: A–M: 10 lm; N: 20 lm.
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calf serum. No deterioration of the viability of EYFP-expressing cells
was observed during cell culture since the cells were similarly respon-
sive to all tested agents after 1 or 4 days of culture.
The medium used for all experiments contained (in mM): 120 NaCl,
4.8 KCl, 1.5 CaCl2, 1.2 MgCl2, 24 NaHCO3, 1 mg/ml BSA and various
agents as indicated. It was gassed with O2:CO2 (94:6%) to maintain a
pH of 7.4. The 2.5 mM amino acid mixture used in some experiments
contained (in mM): 0.5 alanine, 0.5 leucine, 0.75 glutamine and 0.75
lysine.
Diazoxide was a gift from Schering-Plough (Brussels, Belgium).
Adrenaline was obtained from Denolin (Brussels, Belgium) and amino
acids from Merck (Darmstadt, Germany). All other chemicals were
from Sigma (St. Louis, MO).
2.4. Insulin and glucagon secretion experiments
For static determination of insulin and glucagon secretion, overnight
cultured islets were preincubated for 60 min in the presence of 0.5 mM
glucose. Batches of 7 islets were then incubated at 37 C for 60 min in
the presence of the indicated compounds. For perifusion experiments,
batches of 200 overnight cultured islets were transferred into perifusion
chambers [20]. Islets were then perifused at 37 C, at a ﬂow rate of
0.5 ml/min, with test solutions as described in the legends. Insulin
[20] and glucagon (Linco) were measured by radioimmunoassay.
2.5. [Ca2+]c measurements
Cells were loaded at 37 C for 2 h with 2 lM fura PE3-AM (MoBi-
Tec, Go¨ttingen, Germany) in RPMI culture medium. [Ca2+]c was mea-
sured at 37 C by dual wavelength (340 and 380 nm) excitation
microspectroﬂuorimetry as previously described [21]. EYFP expression
did not interfere with fura PE3 ﬂuorescence. a-Cells from control
NMRI mice were identiﬁed by their typical [Ca2+]c response to adren-
aline at the end of the experiments [22,23].
2.6. Immunostaining
To assess the distribution of a-cells in islets from GYY mice, the
whole pancreas was ﬁxed in Bouin Allen’s ﬂuid for 24 h, embedded
in paraﬃn, and processed for immunohistochemistry with a rabbit
polyclonal anti-porcine glucagon antibody (NovoCastra, Newcastle,
UK) as previously described (peroxidase-diaminobenzidine technique)
[24].
To verify the cell speciﬁcity of EYFP expression in RIPYY and
GYY islet cells, cultured cells were ﬁxed for 3 h with 4% paraformal-
dehyde, which preserves endogenous EYFP ﬂuorescence (excitation:
490 nm, emission: 535 nm). The cells were then immunostained for
insulin, glucagon or somatostatin with a mouse monoclonal anti-por-
cine insulin antibody (Chemicon, Temecula, CA), a rabbit polyclonal
anti-porcine glucagon antibody (NovoCastra) or a rabbit polyclonal
anti-porcine somatostatin antibody (gift from W. Gepts, Free Univer-
sity of Brussels, Belgium), respectively. To permit simultaneous obser-
vation of EYFP, insulin, glucagon or somatostatin was detected by the
red ﬂuorescence of Alexa Red 594-conjugated goat anti-mouse IgG
(Molecular Probes, Eugene, OR) and Alexa Red 594-conjugated goat
anti-rabbit IgG (Molecular Probes), respectively.
Detection of EYFP and Alexa Red 594-labelled insulin in GYY
islets was performed with a Nikon microscope equipped with a confo-
cal QLC100 spinning disk (Visitech International, Sunderland, UK).
2.7. Statistical analysis
Results are shown as representative traces or means ± S.E. for the
indicated number of cells or batches of islets from at least three diﬀer-
ent cultures. The statistical signiﬁcance of diﬀerences between means
was assessed by unpaired Student’s t-test, or analysis of variance fol-
lowed by a Newman–Keuls test for multiple comparisons.3. Results
3.1. Cell-speciﬁc expression of EYFP
To assess the cell speciﬁcity of EYFP expression, dispersed
islet cells from GYY mice were processed for glucagon, insulin
or somatostatin immunodetection. As illustrated in Fig. 1A–C,all EYFP-tagged cells were immunoreactive for glucagon.
Counting EYFP-tagged and glucagon positive cells revealed
that 76% a-cells were ﬂuorescent for EYFP (133/176 cells).
Importantly, none of the ﬂuorescent cells was immunostained
for insulin (Fig. 1D–F, M) or somatostatin (Fig. 1G–I), con-
ﬁrming the speciﬁc expression of EYFP in a-cells from GYY
mice. The cell speciﬁcity of EYFP expression was also veriﬁed
in b-cells from RIPYY mice. EYFP ﬂuorescence was observed
only in b-cells (Fig. 1J–L), and 80% b-cells were ﬂuorescent
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intensity between isolated cells does not result from cell dam-
age but rather reﬂects a true diﬀerential expression of EYFP
because a similar heterogeneous ﬂuorescence intensity between
EYFP-expressing cells within intact islets was observed in con-
focal microscopy (not shown).
3.2. Characteristics of GYY mice and islets
Immunodetection of glucagon on pancreatic sections from
GYY mice showed typical distribution of a-cells at the peri-
phery of the islets (Fig. 1N). Physiological parameters of
GYY mice were normal compared to C57BL/6J control mice.
There were no diﬀerences in body weight and plasma glucagon
levels between both strains of mice (Fig. 2A and B). Blood glu-
cose concentrations were similar in fed GYY and C57BL/6J
mice, and the responses to fasting and refeeding were also
comparable (Fig. 2C). Thus, blood glucose decreased by
25% after a 24 h fast and increased similarly after refeeding
in both groups. GYY and C57BL/6J mice also displayed sim-
ilar responses to intraperitoneal insulin administration. The
blood glucose concentration dropped by 40% 60 min after
insulin injection, and the rate of recovery was similar in both
types of mice (Fig. 2D).
We then veriﬁed that expression of Cre recombinase and
EYFP did not impair a- and b-cell function. In the presence
of 20 mM arginine, insulin and glucagon secretion were similar
in islets from GYY and C57BL/6J control mice (Fig. 2E and
F). Increasing the glucose concentration from 0.5 to 15 mMFig. 2. Similarity of in vivo (A–D) and in vitro (E–F) biological parameters b
(ﬁlled columns/ﬁlled circles). A–B: Body-weight (n = 14) and plasma gluca
means ± S.E. C: Fasting-refeeding test: blood glucose in the fed state, afte
means ± S.E. for 7 mice. D: Insulin tolerance test: 0.75 IU/kg insulin was inje
indicated times. Values are means ± S.E. for 8 mice. E–F: Eﬀect of 15 mM gl
the presence of 20 mM arginine. Values are means ± S.E. for 12 batches of is
of mice.stimulated insulin secretion and inhibited glucagon secretion
to a similar extent in both types of islets.
We also compared the insulin and glucagon responses of
islets from GYY mice to those of islets from NMRI mice, an
outbred strain unrelated to C57BL/6J mice. Isolated islets were
perifused in the presence of a 2.5 mM mixture of amino acid to
promote glucagon secretion. In the presence of low glucose
(0.5 mM), the rate of insulin secretion by islets from GYY
and control NMRI mice was low and stable. Increasing the
glucose concentration to 15 mM elicited a similar biphasic
insulin secretion in both types of islets, which was reversed
upon lowering the glucose concentration back to 0.5 mM
(Fig. 3A). Subsequent addition of 10 lM adrenaline had no
eﬀect on basal insulin secretion. Glucagon secretion was stea-
dily elevated in the presence of 0.5 mM glucose. It displayed
similar biphasic changes in islets from GYY and NMRI mice
challenged by 15 mM glucose: an initial short-lived increase
followed by a strong, sustained and reversible inhibition
(Fig. 3B). Adrenaline markedly stimulated glucagon secretion.
The glucagon content of both types of islets was similar
(577 ± 18 and 588 ± 47 pg/islet in NMRI and GYY mice,
respectively).
3.3. [Ca2+]c in cells expressing Cre recombinase and EYFP
To verify that expression of Cre recombinase and EYFP
does not aﬀect [Ca2+]c changes, we ﬁrst tested whether glucose
and drugs acting on ATP-sensitive K+ (KATP) channels induce
normal [Ca2+]c responses in EYFP-expressing b-cells. [Ca
2+]cetween GYY (open columns/open circles) and C57BL/6J control mice
gon levels in the fed state (GYY n = 9; C57BL/6J n = 8). Values are
r a 24 h-fast, and 1 h and 4 h after ad libitum refeeding. Values are
cted intra-peritoneally at t = 0 and blood glucose was measured at the
ucose (G15) on insulin and glucagon secretion from islets incubated in
lets. *P < 0.05 and **P < 0.01 versus 0.5 mM glucose in the same strain
Fig. 3. Similarity of insulin (A) and glucagon (B) secretion between
perifused islets from GYY and NMRI mice. Islets were ﬁrst perifused
in the presence of a 2.5 mM amino acid mixture (mix AA) and 0.5 mM
glucose (G). The glucose concentration was then changed between 0.5
and 15 mM, and 10 lM adrenaline (Adre) was added when indicated.
In B, the scale on the left applies to glucagon secretion between 30 and
90 min, whereas the scale on the right applies to secretion between 85
and 110 min. Traces are means ± S.E. for four experiments with islets
from diﬀerent preparations.
Fig. 4. EYFP and Cre expression do not alter a- or b-cell [Ca2+]c
responses. [Ca2+]c was measured in single EYFP-tagged b-cells from
RIPYY mice (A), single EYFP-tagged a-cells from GYY mice (B, D),
and adrenaline-responsive cells (a-cells) from NMRI mice (C, E). A:
The glucose (G) concentration was increased from 3 to 15 mM, and
50 lM diazoxide (Dz) and 500 lM tolbutamide (Tolb) were added to
the perifusion medium as indicated. The trace is representative of
results obtained in 5 b-cells. B–C: Experiments were performed in the
presence of 0.5 mM glucose (G) throughout, and 10 mM arginine
(Arg) was added as indicated. Traces are means ± S.E. of results
obtained in 6 a-cells from GYY mice (B) and 11 adrenaline-
responsive cells from NMRI mice (C). D–E: Experiments were
performed in the presence of 0.5 mM glucose (G) and a 2.5 mM
amino acid mixture (mix AA) throughout. 100 lM diazoxide (Dz),
100 lM tolbutamide (Tolb) and 10 lM adrenaline (Adr) were added
as indicated. Traces are means ± S.E. of results obtained in 8 a-cells
from GYY mice (D), and 9 adrenaline-responsive cells from NMRI
mice (E).
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ulation with 15 mM glucose elicited a transient drop in [Ca2+]c
followed by an increase with large oscillations. These oscilla-
tions were abolished by 50 lM diazoxide, an opener of KATP
channels, and restored by addition of 500 lM tolbutamide,
that closes the channels (Fig. 4A). These responses are thus
similar to those previously reported for normal b-cells [25,26].
We then compared [Ca2+]c responses in GYY a-cells and
NMRI a-cells identiﬁed by their response to adrenaline
[22,23]. In the presence of 0.5 mM glucose, [Ca2+]c oscillated
in 30% GYY a-cells and in 20% NMRI a-cells, and was
low and stable in the others. This relatively low percentage
of oscillating a-cells under low glucose conditions has been
reported by others [23,27]. Arginine (10 mM), a well-established
glucagon secretagogue, similarly increased [Ca2+]c in both
oscillating (not shown) and non-oscillating a-cells from GYY
(Fig. 4B) and NMRI mice (Fig. 4C) [6]. Over 90% a-cells re-
sponded to arginine in GYY (94%) and NMRI (93%) mice
(Fig. 4B and C). In the presence of a 2.5 mM mixture of amino
acids and 0.5 mM glucose, a-cells from GYY mice displayed
high and oscillating [Ca2+]c (Fig. 4D; note that the oscillations
N. Quoix et al. / FEBS Letters 581 (2007) 4235–4240 4239are largely masked by the averaging). Diazoxide decreased
[Ca2+]c to basal levels. Subsequent addition of 100 lM tolbuta-
mide reversed this eﬀect triggering a reversible and rapid
increase in [Ca2+]c with oscillations or a stable elevation.
Although diazoxide abolished [Ca2+]c oscillations induced by
the mixture of amino acids, it did not prevent the peak of
[Ca2+]c triggered by 10 lM adrenaline, supporting previous
observations that adrenaline mobilizes Ca2+ from intracellular
stores [12]. Similar results were obtained in a-cells from NMRI
mice (Fig. 4E).
These results clearly show that neither Cre recombinase nor
EYFP alters a- and b-cell function, and that GYY mice can
reliably be used to identify and study living a-cells.4. Discussion
This study describes the development of two new transgenic
mouse models, referred to as GYY and RIPYY mice, speciﬁ-
cally expressing the ﬂuorescent EYFP protein in a- or b-cells,
respectively. These mice were obtained by crossing the
ROSA26-EYFP reporter mouse, that has in the locus ROSA26
of its genome a sequence loxP-STOP-loxP-EYFP [16] with
either the Glu-Cre or the RIP-Cre mouse [17]. Other transgenic
mouse models expressing a ﬂuorescent protein in their b-cells
have previously been reported [28,29] and are thus comparable
to the presently described RIPYY mice. In contrast, the GYY
mice are the ﬁrst model with easily recognizable a-cells.
Two strategies are possible to generate transgenic mice
expressing a ﬂuorescent protein in a-cells speciﬁcally. The
expression of a reporter protein could be directly controlled
by the glucagon promoter, but this promoter has been
reported to be weak, compared to, e.g. the insulin promoter
[14,30]. The Cre/loxP strategy circumvents this diﬃculty and
permits stronger expression of the reporter. Indeed, even if
expression of the Cre recombinase driven by the glucagon pro-
moter is weak, it is suﬃcient to allow excision of the loxP-
ﬂanked transcriptional STOP sequence and drive the expres-
sion of EYFP placed under control of the strong promoter
present in the ROSA26 locus. Ampliﬁcation of gene expression
by the Cre/loxP strategy has previously been reported not to
compromise the cellular speciﬁcity of expression [14,30]. How-
ever, EYFP expression was heterogeneous among a-cells,
namely the ﬂuorescence was weaker in some cells than others,
and it was sometimes undetectable. We do not know whether
the lack of detection reﬂects a limitation of our ﬂuorescence
system or corresponds to a true lack of EYFP expression. Sim-
ilar observations have sometimes been reported in studies
using the Cre/loxP strategy [31,32]. It is however not a major
drawback since most (80%) a-cells were labelled by EYFP.
One advantage of our mouse models over other EGFP-
expressing models is that EYFP ﬂuorescence does not interfere
with the widely used ﬂuorescent Ca2+ probes, fura-2 or fura-
PE3. Models expressing EGFP impose the use of the less
bright and less convenient fura-red [28].
To ascertain that GYY mice permit reliable investigation of
a-cell physiology, we assessed whether their a-cells behaved
normally, similarly to those of two mouse strains used as con-
trols, i.e. C57BL/6J and NMRI mice. The GYY mice were
phenotypically normal, the architecture of their islets was unal-
tered, and the insulin and glucagon secretory responses to argi-nine, glucose and adrenaline were normal. Interestingly,
15 mM glucose elicited a biphasic change in glucagon secre-
tion, characterized by an initial, short lived stimulation occur-
ring before insulin secretion increased and a subsequent robust
and sustained inhibition. These observations are compatible
with the hypothesis that glucose exerts both stimulatory and
inhibitory eﬀects on glucagon secretion, but whether these
eﬀects are direct or indirect, involving paracrine factors, is con-
troversial (for review, see [5]), and beyond the scope of this
study. The presence of this biphasic glucagon response in both
NMRI and GYY islets further strengthens the validity of the
GYY mouse model.
Since some cells did not express detectable EYFP levels, it
could be argued that the normal glucagon secretion reﬂects
the response of these cells rather than of EYFP-tagged cells.
This is not the case for several reasons. First, glucose strongly
(90%) inhibited glucagon secretion in perifused islets from
GYY mice. It is unlikely that this robust inhibition reﬂects
the response of the 20% non-EYFP tagged a-cells only. Sec-
ond, the [Ca2+]c responses of EYFP-tagged a-cells to adrena-
line, arginine and KATP channel modulators were similar to
those of NMRI a-cells and those reported by others
[6,22,23]. Moreover, glucose and KATP channel modulators
induced the expected [Ca2+]c responses [25,26] in EYFP-tagged
b-cells from RIPYY mice. All these results indicate that GYY
mice can reliably be used to study a-cell physiology.
Speciﬁc expression of EYFP in a-cells should be useful for a
wide variety of applications including islet cell sorting by ﬂuo-
rescence activated cell sorting (FACS). Thus, sorting a- from
b-cells from non-transgenic animals by FACS usually relies
on diﬀerences in autoﬂuorescence and size between both cell
types [8,33]. This method provides an enriched but not pure
preparation of cells. The a-cell fraction is often contaminated
by PP- and d-cells also present in islets. EYFP-expressing a-
cells from GYY mice should be sorted at almost 100% of pur-
ity. This will help to study the physiology and gene expression
of pure a-cell populations. Developmental biology could also
take advantage of the GYY mouse model. Pancreatic islet cell
lineage and islet diﬀerentiation become increasingly well
understood [34,35]. However, mobility of cells during develop-
ment hampered the study of cell lineages and there is a strong
necessity to develop in vivo labelling techniques to fully under-
stand this process. Therefore, the new GYY mouse model
could provide an interesting tool to spatially track the fate of
a-cell progenitors. Another advantage of these transgenic mice
is the rapid identiﬁcation of a-cells before performing electro-
physiological or imaging experiments. Indeed, progress in our
understanding of the cellular mechanisms controlling glucagon
secretion has been slowed down by the diﬃculty to recognize
living a-cells. GYY mice should help to evaluate [Ca2+]c, met-
abolic and other changes in a-cells in situ and to address major
controversial issues such as the mechanisms by which glucose
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